CancerDrs Find care

Stomach Cancer clinical trials in Kentucky

21 actively recruiting stomach cancer trials at 11 sites across Kentucky.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresec…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05677490
Sites in Kentucky:
  • Flaget Memorial Hospital — Bardstown, Kentucky
  • Commonwealth Cancer Center-Corbin — Corbin, Kentucky
  • Saint Joseph Hospital — Lexington, Kentucky
  • Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
  • Saint Joseph Hospital East — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting NIH

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from wh…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06203600
Sites in Kentucky:
  • Saint Joseph Hospital East — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Kentucky:
  • Research Site — Lexington, Kentucky
  • Research Site — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, a…

Sponsor: AstraZeneca
NCT ID: NCT06764875
Sites in Kentucky:
  • Research Site — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.

Sponsor: AstraZeneca
NCT ID: NCT06346392
Sites in Kentucky:
  • Research Site — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2…

Sponsor: RayzeBio, Inc.
NCT ID: NCT05477576
Sites in Kentucky:
  • Research Facility — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach …

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT06901531
Sites in Kentucky:
  • Saint Elizabeth Medical Center Edgewood — Edgewood, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+),…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06784752
Sites in Kentucky:
  • St Elizabeth Healthcare — Edgewood, Kentucky
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Network

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

This study is being done to answer the following questions: Can we lower the chance of your gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into your abdominal cavity in addition to chemotherapy g…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT07001748
Sites in Kentucky:
  • University of Kentucky/Markey Cancer Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Pa…

Sponsor: Phanes Therapeutics
NCT ID: NCT05482893
Sites in Kentucky:
  • Norton Cancer Institute — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of partici…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06469944
Sites in Kentucky:
  • Norton Hospital-Norton Cancer Institute - Downtown ( Site 6900) — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…

Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Kentucky:
  • Norton Cancer Institute — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Ce…

Sponsor: AbbVie
NCT ID: NCT05005403
Sites in Kentucky:
  • Norton Cancer Institute /ID# 248903 — Louisville, Kentucky
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Kentucky:
  • Flaget Memorial Hospital — Bardstown, Kentucky
  • Commonwealth Cancer Center-Corbin — Corbin, Kentucky
  • Saint Elizabeth Healthcare Edgewood — Edgewood, Kentucky
  • Saint Elizabeth Healthcare Fort Thomas — Fort Thomas, Kentucky
  • Saint Joseph Hospital — Lexington, Kentucky
View on ClinicalTrials.gov →
NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in Kentucky:
  • Flaget Memorial Hospital — Bardstown, Kentucky
  • Commonwealth Cancer Center-Corbin — Corbin, Kentucky
  • Saint Joseph Hospital — Lexington, Kentucky
  • Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
  • Saint Joseph Hospital East — Lexington, Kentucky
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Kentucky:
  • Flaget Memorial Hospital — Bardstown, Kentucky
  • Commonwealth Cancer Center-Corbin — Corbin, Kentucky
  • Saint Joseph Hospital — Lexington, Kentucky
  • Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
  • Saint Joseph Hospital East — Lexington, Kentucky
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer

This phase III trial compares the use of a digital chatbot enabled intervention to standard remote genetic services for increasing uptake of genetic counseling and testing among adolescents and young adult (AYA) cancer patients. Genetic te…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07091617
Sites in Kentucky:
  • Flaget Memorial Hospital — Bardstown, Kentucky
  • Commonwealth Cancer Center-Corbin — Corbin, Kentucky
  • Saint Joseph Hospital — Lexington, Kentucky
  • Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
  • Saint Joseph Hospital East — Lexington, Kentucky
View on ClinicalTrials.gov →
Recruiting Industry

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …

Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Kentucky:
  • Baptist Corbin — Corbin, Kentucky
  • Baptist Hardin — Elizabethtown, Kentucky
  • Baptist Lexington — Lexington, Kentucky
  • Baptist Paducah — Paducah, Kentucky
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20